Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin - Buda, Gabriele; Ricci, Deborah; Huang, C. Chris; Favis, Reyna; Cohen, Nadine; Zhuang, Sen H; Harousseau, Jean-Luc; Sonneveld, Pieter; Bladé, Joan; Orlowski, Robert Z (Annals of hematology, 2010)
Keywords: Adult; Aged; Aged, 80 and over; analogs & derivatives; Antineoplastic Agents; Antineoplastic Agents - therapeutic use; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B - genetics; ATP Binding Cassette Transporter, Subfamily B - metabolism; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 1 - genetics; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Boronic Acids - therapeutic use; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; drug therapy; genetics; Hematology; Humans; Kaplan-Meier Estimate; MDR1; Medicine; Medicine & Public Health; metabolism; Middle Aged; MRP1; Multiple Myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - metabolism; myeloma; Oncology; Original; Original Article; Pegylated liposomal doxorubicin; Polyethylene Glycols; Polyethylene Glycols - therapeutic use; Polymorphism, Single Nucleotide; Pyrazines; Pyrazines - therapeutic use; Recurrence; Retrospective Studies; SNP; therapeutic use; Time Factors; MDR1; MRP1; Bortezomib; SNP; Pegylated liposomal doxorubicin; Multiple myeloma